Oncology Medical News about common immune defect;impaired interferon signaling;human cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Impaired interferon signaling is a common immune defect in human cancer
Proceedings of the National Academy of Sciences of the United States of America, 06/04/09

Critchley-Thorne RJ et al. - In a trial to assess whether altered IFN signaling may be a key mechanism of immune dysfunction common to cancer, it was reported that defects in lymphocyte IFN signaling arise in pts with breast cancer, melanoma, and gastrointestinal cancer, and these defects may represent a common cancer-associated mechanism of immune dysfunction.

Methods

Functional responses to IFN were assessed in peripheral blood lymphocytes from pts with 3 major cancers: breast cancer, melanoma, and gastrointestinal cancer.

Results

Type-I IFN (IFN-α)-induced signaling was reduced in T cells and B cells from all 3 cancer-pt groups vs healthy controls.
Type-II IFN (IFN-γ)-induced signaling was reduced in B cells from all 3 cancer pt groups, but not in T cells or natural killer cells.
Impaired-IFN signaling was equally evident in stage II, III, and IV breast cancer pts, and downstream functional defects in T cell activation were identified.

<< Previous
The histone deacetylase inhibitor LBH589 inhibits expression of...

Next >>
Does hormone treatment added to radiotherapy improve outcome in...